Gaucher’s Disease Pipeline Summary

DelveInsight’s, “Gaucher’s Disease - Pipeline Insight, 2026” report provides comprehensive insights about 14+ companies and 15+ pipeline drugs in Gaucher’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gaucher’s Disease: Understanding

Gaucher’s Disease: Overview

Gaucher disease is a rare, inherited lysosomal storage disorder caused by deficient activity of the enzyme ?-glucocerebrosidase (glucosylceramidase), leading to the accumulation of glucocerebroside within lysosomes of macrophages. It is inherited in an autosomal recessive manner due to pathogenic variants in the GBA1 gene. The disease has a broad clinical spectrum and is classified into three major types based on the presence and progression of neurological involvement. Common manifestations include hepatosplenomegaly, anemia, thrombocytopenia, bone pain, skeletal abnormalities, and, in some forms, progressive neurological impairment.

Gaucher disease is caused by biallelic pathogenic variants in the GBA1 gene, which encodes the lysosomal enzyme ?-glucocerebrosidase. Deficiency of this enzyme impairs the degradation of glucocerebroside into glucose and ceramide, resulting in the progressive accumulation of glucocerebroside within macrophages. These lipid-laden macrophages, known as Gaucher cells, infiltrate various organs, particularly the spleen, liver, bone marrow, and, in neuronopathic forms, the central nervous system, leading to multisystem disease.

The deficiency of ?-glucocerebrosidase results in the lysosomal accumulation of glucocerebroside and glucosylsphingosine within tissue macrophages, forming characteristic Gaucher cells. These cells release inflammatory mediators that contribute to chronic inflammation, tissue damage, and organ dysfunction. Infiltration of Gaucher cells into the spleen, liver, and bone marrow causes hepatosplenomegaly, cytopenias, and skeletal complications, while in neuronopathic forms, substrate accumulation in the central nervous system leads to progressive neurological deterioration.

The diagnosis of Gaucher disease is established by demonstrating reduced ?-glucocerebrosidase enzyme activity in leukocytes or cultured fibroblasts, followed by molecular genetic testing to identify pathogenic variants in the GBA1 gene. Additional evaluations include complete blood counts, liver function tests, imaging studies to assess liver, spleen, and bone involvement, and measurement of disease biomarkers such as chitotriosidase and glucosylsphingosine (lyso-GL1) to support diagnosis and monitor disease burden.

The mainstay of treatment for Gaucher disease is enzyme replacement therapy (ERT), which replenishes deficient ?-glucocerebrosidase and improves hematologic, visceral, and skeletal manifestations. Substrate reduction therapy (SRT) is an alternative for selected patients and works by decreasing the synthesis of glucocerebroside. Supportive care, including pain management, orthopedic interventions, blood transfusions when required, and multidisciplinary monitoring, is important for managing complications. Emerging therapies, including gene therapy, are being investigated to provide long-term correction of the underlying enzyme deficiency.

"Gaucher’s Disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gaucher’s Disease pipeline landscape is provided which includes the disease overview and Gaucher’s Disease treatment guidelines. The assessment part of the report embraces, in depth Gaucher’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gaucher’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Gaucher’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Gaucher’s Disease.

Gaucher’s Disease Emerging Drugs Chapters

This segment of the Gaucher’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gaucher’s Disease Emerging Drugs

• FLT201: Spur Therapeutics

FLT201 is an investigational AAV-based gene therapy being developed for Gaucher disease. The therapy is designed to deliver a functional copy of the GBA1 gene to liver cells using an adeno-associated virus (AAV) vector, enabling sustained production and systemic secretion of the lysosomal enzyme ?-glucocerebrosidase (GCase). The secreted enzyme is subsequently taken up by macrophages and other affected cells via mannose receptor-mediated pathways, restoring deficient GCase activity and promoting the breakdown of accumulated glucosylceramide and glucosylsphingosine. Through this mechanism of action, FLT201 aims to provide durable, long-term enzyme replacement from a single administration, addressing the underlying genetic cause of Gaucher disease. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Gaucher’s Disease.

• LY-M001: Lingyi Biotech Co., Ltd.

LY-M001 is an investigational recombinant adeno-associated virus serotype 8 (rAAV8)-based gene therapy being developed by Lingyi Biotech Co., Ltd. for the treatment of Type 1 Gaucher disease (GD1). The therapy is designed as a one-time intravenous infusion that delivers a functional GBA1 gene to liver cells, enabling long-term production of the lysosomal enzyme glucocerebrosidase (GCase). By restoring GCase activity, LY-M001 aims to reduce the pathological accumulation of glucosylceramide in macrophages, thereby addressing the underlying cause of Gaucher disease rather than providing temporary enzyme replacement. The therapy has demonstrated encouraging early clinical findings and is currently being evaluated in Phase I/II clinical trials in both adult and pediatric patients to assess its safety, tolerability, and efficacy, with dose-escalation and dose-expansion cohorts designed to establish the optimal therapeutic dose. If successful, LY-M001 has the potential to provide a durable, disease-modifying treatment that could reduce or eliminate the need for lifelong enzyme replacement or substrate reduction therapies.

Further product details are provided in the report……..

Gaucher’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Gaucher’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Gaucher’s Disease

There are approx. 14+ key companies which are developing the therapies Gaucher’s Disease. The companies which have their Gaucher’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Spur Therapeutics and others.

• Phases

DelveInsight’s report covers 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Gaucher’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gaucher’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gaucher’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gaucher’s Disease drugs.

Gaucher’s Disease Report Insights

• Gaucher’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gaucher’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gaucher’s Disease drugs?
• How many Gaucher’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gaucher’s Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gaucher’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gaucher’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Spur Therapeutics
• Shanghai Vitalgen BioPharma Co., Ltd.
• Lingyi Biotech Co., Ltd.
• Glafabra Therapeutics

Key Products

• FLT201
• VGN-R08b
• LY-M001
• GT-GBA1-S05